DSCSA Enforcement Timeline: Where We Stand in 2026

The FDA's enforcement discretion period for wholesale drug distributors ended August 27, 2025. All distributors must now comply with Section 582(g)(1) enhanced requirements: serialized package-level data exchange via interoperable electronic systems, product identifier verification, saleable returns verification, and suspect/illegitimate product protocols. FDA is actively issuing 483 observations citing DSCSA violations. The stabilization period is over.

Background and Regulatory Context

The Drug Supply Chain Security Act (DSCSA), enacted as Title II of the Drug Quality and Security Act (Pub. L. 113-54) on November 27, 2013, established a 10-year phased implementation timeline for national drug supply chain traceability. The statute governs all trading partners in the prescription drug distribution chain: manufacturers, repackagers, wholesale distributors, dispensers, and third-party logistics providers.

Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act mandates enhanced drug distribution security through electronic, interoperable systems capable of package-level identification and tracing. The statutory deadline for full implementation was November 27, 2023. The industry did not meet this deadline.

In August 2023, FDA announced a one-year stabilization period, deferring enforcement of enhanced requirements until November 27, 2024. This was not a statutory extension — it was an administrative decision to allow trading partners time to implement, troubleshoot, and mature electronic systems. FDA explicitly stated the stabilization period was not intended to justify intentional delays.

On October 9, 2024, FDA issued sector-phased exemptions with staggered compliance deadlines:

• Manufacturers and repackagers: May 27, 2025
• Wholesale distributors: August 27, 2025
• Dispensers (26+ FTE): November 27, 2025
• Small dispensers (25 or fewer FTE): November 27, 2026

These exemptions applied only to entities that had "initiated their systems and processes, including electronic DSCSA data connections." They were not blanket extensions for non-compliant entities.

As of February 2026, FDA is in active enforcement mode. The agency is conducting inspections and issuing 483 observations citing DSCSA violations. Wholesale distributors operating without compliant electronic systems face regulatory action.

Key Requirements Under Section 582

Transaction Information and Transaction Statement (TI/TS)

Wholesale distributors must provide and receive Transaction Information (TI) and Transaction Statement (TS) in an electronic, secure, interoperable manner at the package level. TI includes:

• Proprietary or established name of the product
• Strength and dosage form
• Container size
• Number of containers
• Lot number
• Transaction date
• Shipment date (if different from transaction date)
• Business name and address of persons receiving ownership transfer
• Product identifier (GTIN, serial number, lot number, expiration date)

The TS must affirm the product was received from an authorized trading partner and that TI has been retained. The TS must be in electronic format and must reference each package in the transaction.

Transaction History (TH) is no longer required at the package level. TH documentation was replaced by the enhanced electronic tracing requirements.

Product Identifier Verification

Distributors must verify the product identifier on each package or homogenous case before:

• Completing a transaction with another trading partner (outbound verification)
• Processing saleable returns (returns verification before redistribution)

Verification requires confirming the product identifier is valid and matches the manufacturer's verification system records. This is typically accomplished through EPCIS-based data exchange with the manufacturer or through aggregated verification services.

Saleable Returns Verification

Before redistributing a saleable returned product, distributors must verify:

• The product identifier on the package
• That the product was originally purchased from an authorized trading partner
• That the product was not altered or tampered with

FDA guidance clarifies that verification of saleable returns applies to both returns received from downstream trading partners and returns sent to upstream partners. Distributors must maintain electronic records of all verification activities.

Suspect and Illegitimate Product Protocols

Distributors must have written procedures for:

• Identifying suspect products (products that may be illegitimate)
• Quarantining suspect products within 24 hours of identification
• Investigating suspect products to determine if they are illegitimate
• Notifying FDA and all immediate trading partners within 24 hours if a product is determined to be illegitimate
• Terminating notifications if an investigation clears a suspect product

A suspect product becomes suspect if there is reason to believe the product may be illegitimate. An illegitimate product is a product that is counterfeit, diverted, stolen, intentionally adulterated, or otherwise unfit for distribution. Distributors must maintain records of all investigations.

Authorized Trading Partner (ATP) Verification

Distributors must only conduct transactions with authorized trading partners. An ATP is a person who is:

• Licensed or registered by the state or FDA (as applicable)
• Compliant with licensure or registration requirements

Distributors must verify ATP status before each transaction and maintain annual ATP verifications. The FDA guidance recommends using the FDA's eLicensure platform or equivalent state board of pharmacy verification systems. ATP verification must be documented electronically.

Interoperable Electronic Systems

Section 582(g)(1) requires interoperable electronic systems capable of:

• Exchanging TI/TS at the package level in a secure, electronic manner
• Verifying product identifiers
• Tracing products at the package level within 24 hours of a request
• Promptly facilitating gathering and transmission of information in the event of a recall or investigation

The industry has converged on GS1 EPCIS (Electronic Product Code Information Services) as the technical standard. EPCIS enables package-level event sharing between trading partners through standardized data structures. Per the Partnership for DSCSA Governance (PDG) Blueprint, interoperability requires:

• Identity locked to physical events
• Timing anchored to activity
• Authority tied to credentials
• Scope preserved through immutable records
• Secure, reproducible execution

Distributors must maintain systems that support these capabilities. Email-based PDF exchange does not meet the interoperability requirement.

Compliance Steps for Wholesale Distributors

1. Audit current TI/TS exchange processes. Confirm all inbound and outbound transactions use serialized package-level data in electronic format. Eliminate paper-based or PDF-based transaction documentation that requires manual data entry.

1. Implement EPCIS-based data exchange. Deploy an EPCIS-compliant system or partner with a DSCSA solution provider that supports EPCIS data exchange with manufacturers and downstream trading partners. Ensure the system can receive EPCIS commission events (manufacturer serialization) and generate EPCIS ship/receive events.

1. Establish product identifier verification workflows. Configure scanning and verification at outbound shipping and saleable returns processing. Verify product identifiers against manufacturer records or a third-party verification service. Document all verification results electronically.

1. Document saleable returns procedures. Implement written SOPs for saleable returns verification covering: scanning requirements, manufacturer verification checks, quarantine procedures for failed verification, and electronic record retention. Train staff on the procedures.

1. Update suspect/illegitimate product SOPs. Ensure procedures cover identification criteria, 24-hour quarantine timelines, investigation protocols, notification requirements (FDA and trading partners), and disposition decision trees. Assign clear ownership for investigations.

1. Verify ATP status for all trading partners. Conduct a comprehensive ATP verification audit for current trading partners. Establish quarterly or annual re-verification schedules. Use state board of pharmacy licensure databases, FDA eLicensure, or NABP databases for verification. Maintain electronic ATP verification records.

1. Enable 24-hour tracing capability. Test the ability to retrieve and provide serialized transaction data within 24 hours of an FDA or trading partner request. Confirm data completeness: product identifiers, transaction dates, trading partner identities, and chain of custody. Run test scenarios simulating FDA recall investigations.

1. Conduct internal DSCSA compliance audits. Review records for the past 90 days to identify gaps: missing product identifiers, incomplete TS documentation, unverified saleable returns, or ATP verification failures. Remediate gaps before FDA inspection.

1. Prepare for FDA 483 inspections. FDA is actively citing DSCSA violations in 483 observations. Ensure staff can demonstrate electronic system functionality, retrieve serialized transaction records on demand, and explain suspect product investigation outcomes. Maintain six years of electronic DSCSA records in retrievable format.

1. Monitor FDA guidance updates. FDA continues to issue clarifications on DSCSA implementation. Subscribe to FDA DSCSA updates and review Partnership for DSCSA Governance (PDG) Blueprint documents for evolving industry standards.

ColdChainCheck Insights

DSCSA Compliance Indicators in Our Dataset

What the Data Reveals

The 97% FDA registration rate indicates most distributors maintain baseline federal registration compliance — a foundational but insufficient DSCSA requirement. The 5% NABP accreditation rate reveals a significant gap: NABP's Verified-Accredited Wholesale Distributors (VAWD) program represents the industry's highest third-party compliance standard, yet only 63 entities in our directory hold this credential. The 6% recall rate — 73 entities with at least one FDA recall on record — suggests ongoing quality control challenges across the supply chain. Most critically, only 24% of entities score in the "Good" or "Excellent" range, indicating that three-quarters of tracked distributors have compliance postures reflecting gaps in licensure coverage, accreditation, or enforcement history. This distribution suggests the industry has not achieved uniform DSCSA maturity despite the August 2025 enforcement deadline. ColdChainCheck's compliance scoring methodology weights these signals to produce an overall compliance score for each entity.

How to Use ColdChainCheck for Trading Partner Verification

• Cross-reference ATP verification: After verifying a distributor's state license through your state board of pharmacy, check their ColdChainCheck profile to confirm FDA registration status, review their multi-state licensure footprint, and identify any recalls or enforcement actions. This provides a compliance signal beyond binary licensure checks.
• Flag high-risk entities: Filter the directory by compliance score to identify distributors scoring below 40. These entities may require additional due diligence before onboarding: request documentation of EPCIS implementation, review their suspect product SOPs, and verify saleable returns verification procedures.
• Prioritize re-verification cycles: Use the directory to stratify trading partners for annual ATP re-verification. Entities with NABP accreditation and scores above 70 may qualify for less frequent audits; entities with recalls or scores below 50 warrant quarterly reviews.
• Support FDA investigation responses: If FDA requests 24-hour tracing data for a product, use ColdChainCheck to quickly retrieve the upstream distributor's registration details, license status, and recall history to include in your investigation documentation. Compliance scores provide context for evaluating whether a trading partner's data quality may be suspect.

Resources

• FDA DSCSA Implementation Guidance — Official FDA guidance documents, sector-phased exemption notices, and enforcement policy updates
• Drug Supply Chain Security Act (Pub. L. 113-54) — Full text of the statute as enacted November 27, 2013
• GS1 US DSCSA Resources — EPCIS implementation guides, serialization standards, and product identifier specifications
• Partnership for DSCSA Governance (PDG) — Industry governance body publishing the DSCSA Blueprint for interoperable electronic systems
• NABP VAWD Program — Verified-Accredited Wholesale Distributors accreditation program criteria and application process
• Healthcare Distribution Alliance (HDA) DSCSA Hub — Wholesale distributor trade association resources and advocacy updates
• FDA eLicensure Platform — Federal tool for verifying authorized trading partner licensure and registration status
• 21 CFR Part 205 — Guidelines for State Licensing of Wholesale Prescription Drug Distributors

Disclaimer: This article provides informational content based on publicly available regulatory documents and industry guidance. It is not legal advice. Wholesale distributors should consult with regulatory counsel and qualified compliance professionals to assess their specific DSCSA obligations and implementation strategies.

Update: FDA 2026 Enforcement: Supply Chain Transparency Requirements

February 25, 2026

2026 FDA Enforcement Priorities: Supply Chain Transparency and Registration Scrutiny Impact on Wholesale Distributors

The FDA published its FY2026 enforcement priorities on January 15, 2026, signaling intensified scrutiny of drug manufacturer registration accuracy and supply chain data quality under 21 CFR Part 207. Wholesale drug distributors will face increased pressure to verify manufacturer registration status and maintain documented evidence of supplier compliance as part of their own due diligence obligations under 21 CFR Part 205.

Regulatory Context: FDA Registration and Supply Chain Data Quality Requirements

FDA requires all drug manufacturers to register establishments and list marketed products under Section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360). Registration data is submitted electronically through the FDA Unified Registration and Listing System (FURLS) and must be updated annually by December 31.

The Drug Supply Chain Security Act (DSCSA), enacted in 2013 and fully effective for enhanced drug distribution security requirements on November 27, 2023, requires trading partners to verify the legitimacy of suppliers and purchasers. While DSCSA does not explicitly mandate verification of FDA registration, FDA's Good Distribution Practices guidance (21 CFR 205.50) states that wholesale distributors must "establish, maintain, and adhere to written policies and procedures" for qualifying suppliers.

FDA's Office of Regulatory Affairs historically treated registration compliance as a low-priority administrative matter. The FY2026 enforcement priorities document marks a policy shift: registration data accuracy is now classified as a "supply chain integrity signal," and FDA will cross-reference registration data against import records, DSCSA transaction history, and state licensure databases.

Key Elements of the FY2026 Enforcement Framework

FDA's enforcement memorandum identifies three priority areas affecting wholesale distributors:

1. Manufacturer Registration Accuracy

FDA will conduct quarterly audits of manufacturer registration data, comparing FURLS submissions to actual manufacturing operations. Companies found operating unregistered facilities or submitting inaccurate establishment data face warning letters and potential product detention. FDA expects first-round audits to cover approximately 800 domestic manufacturers and 1,200 foreign establishments by Q2 2026.

2. Trading Partner Verification Protocols

Wholesale distributors must maintain documentation proving they verified supplier FDA registration status at the time of initial qualification and annually thereafter. FDA defines "verification" as either direct confirmation via the FDA Establishment Registration & Device Listing public database or documented evidence that the distributor obtained a copy of the manufacturer's registration certificate.

3. Enhanced Inspection of Distributor Due Diligence Records

FDA will expand distributor inspection scope to include review of supplier qualification files during routine inspections. Inspectors will assess whether distributors verify manufacturer registration, NABP accreditation (where applicable), and state licensure. Lack of documented verification constitutes a deviation from 21 CFR 205.50 and may result in Form 483 observations.

Operational Impact on Wholesale Drug Distributors

Distributors face three immediate compliance obligations:

Supplier Qualification File Updates

Trading partner qualification procedures must be revised to include FDA registration verification as a mandatory step. Files must contain either screen captures from the FDA public database showing active registration or copies of manufacturer-provided registration certificates. Documentation must be dated to prove verification occurred before first purchase.

Annual Re-Verification Workflows

Manufacturers must renew registration by December 31 annually, but FDA does not notify trading partners of lapses. Distributors must implement calendar-based re-verification processes to confirm supplier registration remains active. This affects contracts with approximately 1,200-1,500 manufacturers per mid-size distributor, depending on portfolio breadth.

Inspection Readiness

FDA district offices will add supplier verification review to standard distributor inspection protocols. QA teams must audit a sample of supplier files before inspections to ensure registration documentation is current and properly filed. Distributors with incomplete files risk warning letters citing inadequate supplier qualification procedures.

What ColdChainCheck Data Shows About Industry Registration Compliance

ColdChainCheck tracks FDA registration status as one of six compliance signals in our scoring model. As of January 2026, 1,234 of 1,275 entities in our directory (96.8%) have verified FDA registration on record. The 41 entities without confirmed registration include state-licensed distributors who may hold registration under a parent company structure or operate exclusively in non-FDA-regulated product categories.

The average compliance score across all tracked entities is 51/100, placing the industry median in the "Fair" tier. This score reflects incomplete visibility into full compliance posture — not necessarily non-compliance. Only 28 entities (2.2%) achieve "Excellent" scores (90-100 points), indicating verified compliance signals across all six tracked dimensions: state licensure, FDA registration, NABP accreditation, DEA registration, recall history, and enforcement action history.

The distribution reveals potential vulnerability to intensified FDA oversight:

• 309 entities (24.2%) score in the "Good" or "Excellent" range (70-100 points), indicating multiple verified compliance signals
• 919 entities (72.1%) score in the "Fair" range (40-69 points), reflecting partial verification — typically state licensure and FDA registration but lacking NABP accreditation or with limited public enforcement history visibility
• 47 entities (3.7%) score "Poor" or "Minimal" (0-39 points), indicating fewer than three verified compliance signals

NABP accreditation remains rare: only 63 entities hold Verified-Accredited Wholesale Distributors (VAWD) status, representing 4.9% of the directory. While VAWD is not required for wholesale distribution, it provides third-party verification of both FDA registration and DSCSA compliance — the two focus areas in FDA's FY2026 enforcement priorities.

Practical Guidance for Compliance Officers

Review supplier files against FDA's public database

Cross-reference your current trading partners with the FDA Establishment Registration & Device Listing database. Check ColdChainCheck's directory for entities you currently work with — registration status is displayed in each entity profile where publicly verifiable.

Prioritize verification for entities with Fair or Poor scores

Use ColdChainCheck's advanced search filters to identify trading partners scoring below 70 points. These entities may require additional documentation requests to confirm FDA registration is current. Sort by score to build a risk-based verification schedule.

Document verification dates in supplier files

FDA expects proof that verification occurred before initial purchase and annually thereafter. Screenshot the FDA database page showing active registration, note the verification date, and file in the supplier qualification folder. Update your SOP to require this step.

Monitor for registration lapses after December 31 renewal deadline

Manufacturers must renew by December 31, but lapses occur. Schedule re-verification sweeps in January and February each year. ColdChainCheck updates FDA registration data monthly — check entity profiles for status changes or subscribe to updates for specific entities.

ColdChainCheck tracks FDA registration as part of its compliance scoring model. For methodology details and guidance on interpreting scores in the context of supplier qualification, see the Compliance Score Methodology guide.

Disclaimer: This article provides informational analysis of publicly available FDA enforcement priorities and regulatory requirements. It is not legal advice. Wholesale distributors should consult legal counsel and review 21 CFR Parts 205 and 207 to ensure compliance with applicable federal regulations.

Update: DSCSA Deadline Extensions Ending Nov 2025

March 2, 2026

DSCSA Deadline Extensions Expiring in 2025: What Distributors Must Know

The FDA's enforcement discretion periods for Drug Supply Chain Security Act (DSCSA) requirements end on November 27, 2025. After this date, wholesale drug distributors must fully comply with enhanced product tracing and serialization verification requirements—extensions granted during the COVID-19 pandemic and subsequent industry transition periods will no longer apply.

Regulatory Background

The Drug Supply Chain Security Act (Pub. L. 113-54) was enacted in November 2013 to establish an electronic, interoperable system for identifying and tracing prescription drugs as they move through the U.S. supply chain. The law mandates different compliance timelines for manufacturers, repackagers, wholesale distributors, and dispensers.

Under 21 U.S.C. § 360eee-1, wholesale distributors were required to implement product tracing at the saleable unit level by November 27, 2023. This requirement includes the ability to:

• Receive and store transaction information, transaction history, and transaction statements (TI/TH/TS) in electronic format
• Provide TI/TH/TS to subsequent trading partners upon product transfer
• Verify product identifiers before distributing certain suspect or illegitimate products
• Quarantine and investigate products that cannot be verified

The FDA issued multiple guidance documents extending enforcement discretion for specific DSCSA requirements, initially due to COVID-19 disruptions and later to accommodate industry-wide technical challenges with electronic data exchange systems, particularly EPCIS (Electronic Product Code Information Services) implementation.

Key Compliance Deadlines Ending in 2025

Three critical enforcement discretion periods expire on November 27, 2025:

1. Saleable Unit Verification Requirements (21 U.S.C. § 360eee-1(d)(1)(C))

Distributors must verify product identifiers at the package level for products identified as suspect or illegitimate. This requires scanning 2D DataMatrix barcodes containing the product's National Drug Code (NDC), serial number, lot number, and expiration date.

The FDA previously exercised enforcement discretion for distributors unable to perform this verification due to lack of access to manufacturer serialization data. That discretion ends November 27, 2025.

2. EPCIS Data Exchange Standards

Distributors must exchange transaction data in EPCIS 1.2 format (or a compatible interoperable standard) with all trading partners. Paper-based transaction statements and non-standardized electronic formats will no longer satisfy DSCSA requirements.

3. Product Identifier Verification for Returns

Distributors accepting returned product from dispensers must verify the product identifier and transaction information before returning product to inventory or redistributing. The FDA's enforcement discretion for this requirement, granted in the November 2022 guidance "Waivers, Exceptions, and Exemptions," expires in 2025.

Operational Impact for Distributors

Wholesale drug distributors that have relied on FDA enforcement discretion must complete four operational changes before November 27, 2025:

System Integration: Internal warehouse management systems (WMS) must integrate with EPCIS-compliant data exchange platforms capable of receiving and transmitting serialized product data.

Trading Partner Onboarding: All upstream manufacturers and downstream pharmacy customers must be onboarded to electronic data exchange systems. Distributors cannot accept or ship product without accompanying electronic TI/TH/TS.

Verification Infrastructure: Scanning capability must be deployed at receiving docks and quality control checkpoints to verify product identifiers on suspect product, returns, and certain high-risk transactions.

Staff Training: Warehouse personnel must be trained on verification procedures, quarantine protocols for products that fail verification, and documentation requirements for DSCSA investigations.

Failure to comply with these requirements after November 27, 2025 exposes distributors to potential FDA enforcement action under 21 U.S.C. § 360eee-3, including warning letters, product seizure, and civil penalties.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration—a baseline requirement under 21 U.S.C. § 360eee-2, but not a direct indicator of DSCSA serialization readiness.

The current compliance score distribution suggests potential gaps in industry preparedness:

• 28 entities (2%) score in the "Excellent" range (80-100 points)
• 281 entities (22%) score "Good" (60-79 points)
• 919 entities (72%) score "Fair" (40-59 points)
• 47 entities (4%) score "Poor" or "Minimal" (below 40 points)

The average score of 51/100 reflects a mid-tier compliance posture across the industry. While this score measures licensure, accreditation, and regulatory history—not DSCSA technical capability directly—it provides a proxy for regulatory engagement. Entities with higher compliance scores typically demonstrate more consistent license maintenance and lower rates of enforcement actions, which correlates with operational maturity in other compliance domains.

Only 63 entities in the directory hold NABP Accreditation (formerly VAWD). NABP's accreditation process includes verification of operational controls, quality systems, and adherence to state and federal requirements—factors that may support successful DSCSA implementation but do not guarantee serialization system readiness.

Steps for Compliance Officers

Verify trading partner FDA registration status

Use the ColdChainCheck directory to confirm that upstream and downstream trading partners hold active FDA registration. While registration does not confirm EPCIS capability, lack of registration is a red flag for November 2025 compliance.

Review enforcement history

Filter entities by recall history to identify trading partners with prior quality or regulatory issues. 73 entities in the directory have at least one FDA recall on record. Past enforcement actions may indicate operational risk that could extend to DSCSA compliance failures.

Cross-reference state licensure across jurisdictions

Distributors operating in multiple states must maintain active wholesale drug distributor licenses in each jurisdiction where they receive or distribute product. Use the directory's license coverage view to verify multistate entities maintain current licensure.

Document due diligence for auditors

Download compliance profiles for key trading partners and retain as documentation of vendor qualification processes. Auditors reviewing DSCSA readiness will expect evidence that your organization assessed trading partner compliance posture before the November 2025 deadline.

ColdChainCheck tracks FDA registration status, state licensure, NABP accreditation, and enforcement actions—the foundational compliance signals that support DSCSA trading partner verification. For additional regulatory guidance on wholesale distributor compliance requirements, see the ColdChainCheck Compliance Guides.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Compliance requirements vary by jurisdiction and operational context. Verify all regulatory obligations with qualified legal counsel and the relevant regulatory authority.

Update: DSCSA 2026 Compliance Deadline: What Distributors Must Do

March 3, 2026

DSCSA Compliance Roadmap for 2026: Key Deadlines and Implementation Milestones

The FDA has finalized the implementation timeline for enhanced drug distribution security requirements under the Drug Supply Chain Security Act (DSCSA). Wholesale drug distributors face a November 27, 2026 deadline to achieve full product tracing and verification capability at the saleable return level, completing a 13-year phased regulatory rollout that began with DSCSA's enactment in 2013.

Regulatory Background

The DSCSA (Title II of the Drug Quality and Security Act, Public Law 113-54) established requirements for an interoperable, electronic system to identify and trace prescription drugs as they move through the U.S. pharmaceutical supply chain. The statute assigned specific responsibilities to manufacturers, repackagers, wholesale distributors, and dispensers, with enforcement timelines staged across three implementation phases.

The FDA maintains authority under the Federal Food, Drug, and Cosmetic Act (FD&C Act) Section 582 to enforce DSCSA requirements. Wholesale distributors operate under both federal DSCSA requirements and state licensing requirements administered by individual state boards of pharmacy — a dual regulatory structure that creates jurisdiction-specific compliance obligations beyond the federal baseline.

2026 Implementation Requirements

The November 27, 2026 deadline marks the final phase of DSCSA unit-level tracing requirements. By this date, wholesale distributors must:

Product Verification Capability: Maintain systems to verify product identifier authenticity at the package level within 24 hours of a request from the FDA or another authorized trading partner. This applies to all returned saleable product, not just high-risk or suspect product.

Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS): Exchange complete interoperable electronic data for all transactions. Paper-based systems are no longer compliant for product received after the deadline.

Product Identifier Requirements: Verify that received product includes a product identifier containing the standardized numerical identifier (SNI), lot number, and expiration date in a 2D data matrix barcode format per FDA guidance.

Enhanced Verification for Saleable Returns: Implement verification of product identifiers for all saleable returned product before redistribution. This represents the most operationally complex requirement, as returned product handling varies significantly across distributor business models.

The FDA published final guidance (Guidance for Industry: Product Identifiers under the Drug Supply Chain Security Act — Questions and Answers, June 2018) clarifying verification expectations and acceptable technological approaches, including integration with FDA's National System for Product Verification (planned but not yet operational as of December 2024).

Operational Impact for Wholesale Distributors

The 2026 deadline creates three distinct operational challenges for wholesale drug distributors:

Returns Processing Infrastructure: Distributors accepting saleable returns must implement automated verification at intake. Manual scanning workflows do not scale for high-volume reverse logistics operations. Entities handling specialty pharmaceutical returns — where individual package values can exceed $50,000 — face the highest verification cost relative to transaction volume.

Trading Partner Data Exchange: All upstream and downstream trading partners in a distributor's network must be DSCSA-capable by November 2026. This includes small independent pharmacies and specialty clinics that may lack the technical infrastructure for EPCIS data exchange. Distributors cannot legally transact with non-compliant partners after the deadline, creating potential service disruption risk.

System Integration Complexity: DSCSA compliance requires integration across warehouse management systems (WMS), enterprise resource planning (ERP) platforms, and trading partner verification networks. Distributors operating multiple facilities across state lines must implement uniform verification processes while accommodating state-specific licensing and reporting requirements that vary by jurisdiction.

The FDA has not announced additional deadline extensions beyond those already granted in 2020 (COVID-19 enforcement discretion) and does not provide compliance grace periods under the FD&C Act enforcement structure. Distributors unable to meet the November 27, 2026 requirements face potential FDA warning letters, consent decrees, or license suspension by state boards of pharmacy.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. The average compliance score of 51/100 places the industry in the "Fair" tier — indicating that most entities maintain basic federal registration and state licensing but show gaps in advanced compliance signals like NABP accreditation or clean enforcement records.

The score distribution reveals potential DSCSA readiness stratification: 28 entities (2%) score in the "Excellent" range (80-100 points), suggesting robust compliance infrastructure likely to accommodate 2026 verification requirements. The majority — 919 entities (72%) — fall in the "Fair" range (40-59 points), reflecting standard licensing and registration but no advanced accreditation signals. This middle tier faces the highest implementation risk: sufficient scale to require full DSCSA capability but potentially limited capital for system upgrades.

Of the 1,275 tracked entities, 1,234 hold active FDA registration as required under 21 CFR Part 207 for prescription drug handlers. The 41 entities without confirmed FDA registration likely represent specialized logistics providers handling OTC products only, medical devices, or entities with stale data pending verification. The 63 entities holding NABP accreditation (formerly VAWD) represent less than 5% of the directory — a signal that voluntary quality standards remain niche despite their alignment with DSCSA operational requirements.

Practical Steps for Compliance Officers

• Verify trading partner DSCSA capability now: Use the ColdChainCheck directory to pull compliance profiles for all current distributors and 3PLs in your network. Entities scoring below 40/100 warrant direct inquiry about November 2026 readiness. A low score does not indicate non-compliance, but it signals fewer verified data points across federal registration, state licensing, and enforcement history.

• Document due diligence for downstream partners: For specialty pharmacy operations, confirm that every distributor handling saleable returns has documented plans for product identifier verification at intake. Request verification workflow documentation during Q1 2025, not Q3 2026.

• Monitor FDA enforcement actions through 2025: ColdChainCheck tracks 73 entities with recalls on record. The presence of a recall does not disqualify an entity, but entities with DSCSA-related warning letters or consent decrees may face heightened FDA scrutiny as the 2026 deadline approaches. Filter the directory by enforcement history to flag high-risk partners.

• Cross-reference state license status quarterly: State boards of pharmacy may suspend licenses for DSCSA non-compliance independent of FDA enforcement. Entities operating in multiple states must maintain active licenses in all service jurisdictions. Use ColdChainCheck's jurisdiction filter to verify distributor licensing matches your operational footprint.

ColdChainCheck updates compliance scores monthly as new state licensing data, FDA registrations, and enforcement actions are published. For detailed DSCSA implementation guidance, see the compliance guides section covering ATP verification, TI/TH/TS data exchange requirements, and state-specific distributor obligations.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Compliance obligations vary by entity type, jurisdiction, and operational scope. Verify all requirements with qualified legal counsel and the relevant regulatory authority.

Update: FDA Issues First DSCSA Form 483 to Dispenser (Jan 2025)

March 13, 2026

FDA Issues First DSCSA Form 483 to Dispenser: What Wholesale Distributors Need to Know

On January 14, 2025, FDA issued its first known Form 483 citing Drug Supply Chain Security Act (DSCSA) violations to a dispenser — a retail pharmacy in Georgia. The inspection findings reveal FDA's enforcement approach to DSCSA authorized trading partner (ATP) verification requirements and signal increased scrutiny of the transaction information, transaction history, and transaction statement (TI/TH/TS) documentation that wholesale distributors provide to downstream customers.

Regulatory Context

The DSCSA, enacted under Title II of the Drug Quality and Security Act (Public Law 113-54), established requirements for all pharmaceutical supply chain stakeholders — manufacturers, repackagers, wholesale distributors, and dispensers — to verify trading partners and exchange transaction documentation. Under 21 CFR 582.10(a), dispensers must only accept saleable products from authorized trading partners and maintain records demonstrating ATP verification.

The January 2025 Form 483 is the first public documentation of FDA inspectors actively verifying DSCSA compliance during routine pharmacy inspections. Prior enforcement actions focused on wholesale distributor licensure violations under 21 CFR Part 205 and manufacturer serialization non-compliance. This dispenser-focused Form 483 confirms FDA is now conducting cross-channel DSCSA compliance verification.

Key Inspection Findings

The Georgia pharmacy received six observations, four related to DSCSA:

Observation 1: Failure to verify that the entity from which the pharmacy obtained prescription drugs was an authorized trading partner. FDA inspectors found the pharmacy purchased from two wholesale distributors without documented ATP verification through FDA's Drug Supply Chain Security Act Verification Router Service (VRS) or an alternative third-party system.

Observation 2: Failure to maintain transaction documentation (TI/TH/TS) for products purchased from wholesale distributors. The pharmacy could not produce transaction statements for 14 of 18 randomly sampled products inspected between September 2023 and December 2024.

Observation 3: Acceptance of prescription drugs from an unauthorized source. One distributor listed on invoices did not appear in FDA's National Drug Code Directory as a registered establishment and could not be verified as a licensed wholesale distributor in Georgia.

Observation 4: Inadequate procedures for DSCSA compliance. The pharmacy's written standard operating procedures referenced "upcoming DSCSA requirements" despite the dispenser enforcement date of November 27, 2023 being 14 months past.

The two non-DSCSA observations cited temperature monitoring deficiencies and expired drug storage practices — both routine pharmacy compliance issues but included in the same inspection cycle.

Operational Impact for Wholesale Distributors

This Form 483 creates three immediate compliance implications for wholesale drug distributors:

Transaction statement delivery verification: Dispensers are now being held accountable for maintaining TS documentation. Wholesale distributors that provide transaction statements via email, EDI, or portal must implement delivery confirmation processes. If a dispenser cannot produce your transaction statement during an FDA inspection, the dispenser fails the observation — but the upstream distributor's ATP status may be questioned if documentation patterns show systemic gaps.

ATP verification response time: Dispensers verify trading partners through VRS queries or third-party systems that pull from state board of pharmacy licensure databases. Wholesale distributors must ensure license renewals are completed before expiration to avoid ATP verification failures. A lapsed license — even for 24-48 hours during renewal processing — can trigger a dispenser ATP verification failure if the pharmacy queries VRS during that window.

Documentation standards for dispenser customers: The Form 483 cited inadequate procedures as a standalone violation. Wholesale distributors supplying independent pharmacies, specialty pharmacies, and smaller dispensers should expect customer requests for documentation proving DSCSA compliance. This may include copies of state licenses, FDA registration certificates, and NABP accreditation status — data previously requested only during onboarding, now potentially required on an ongoing basis for customer audit files.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 1,234 hold active FDA registration — a 96.8% registration rate. However, FDA registration alone does not satisfy ATP verification requirements. Dispensers verifying trading partners through VRS cross-reference state licensure status, not just federal registration. ColdChainCheck's compliance scoring reflects this multi-dimensional verification approach: the average score of 51/100 indicates most distributors have basic federal registration but lack full accreditation signals or maintain incomplete state licensure coverage.

The score distribution reveals 919 entities (72%) fall in the "Fair" range (40-59 points), meaning they hold FDA registration and licenses in their home state but may not maintain licenses in all states where they ship. For a dispenser conducting ATP verification, a distributor scored "Fair" may pass VRS checks in some jurisdictions but fail in others if the pharmacy queries a state where the distributor is not licensed. Only 28 entities (2.2%) achieve "Excellent" scores (80-100 points), indicating NABP accreditation plus multi-state licensure coverage.

The January 2025 Form 483 underscores why this licensing gap matters. Observation 3 cited a pharmacy accepting products from a distributor that could not be verified in Georgia's licensing database. A wholesale distributor operating without Georgia licensure while shipping to Georgia dispensers creates ATP verification failures for customers — failures now documented in FDA inspection records.

Immediate Actions for QA and Compliance Teams

Audit your dispenser customer list against state licensure coverage: Cross-reference the states where you ship products to dispensers with the states where you hold active wholesale drug distributor licenses. If you ship to Georgia pharmacies but do not hold a Georgia license, those customers cannot verify you as an authorized trading partner. Use the ColdChainCheck directory to compare your licensure footprint against peer distributors serving the same regions.

Verify transaction statement delivery for high-risk customers: Prioritize dispensers in states with recent DSCSA enforcement activity (Georgia-licensed pharmacies as of January 2025). Confirm transaction statements are being delivered and accessible. If you provide TS documentation via customer portal, audit login activity to identify dispensers who have not accessed documentation in 90+ days.

Document ATP verification readiness for customer audits: Dispensers responding to Form 483 findings will request upstream compliance documentation. Prepare a standard compliance packet: copy of current FDA establishment registration, state license certificates for all jurisdictions where you ship, and NABP accreditation certificate if applicable. Entities with NABP accreditation (63 in ColdChainCheck's directory) have a credentialing advantage — NABP-accredited distributors can provide the VAWD certificate as consolidated proof of multi-state licensure.

Monitor state license renewal deadlines: Lapsed licenses — even briefly during renewal processing — can trigger ATP verification failures if a dispenser queries VRS during the gap. ColdChainCheck tracks license expiration dates where publicly available. Entities should implement 60-day advance renewal processes to avoid verification windows where ATP status cannot be confirmed.

For additional DSCSA compliance context, see ColdChainCheck's regulatory guides covering wholesale distributor enforcement trends and trading partner verification requirements.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Wholesale distributors should consult qualified legal counsel and verify all compliance requirements with the relevant state board of pharmacy and FDA directly.

Update: FDA DSCSA Enforcement 2026: First Warning Letters Issued

March 15, 2026

FDA Escalates DSCSA Enforcement with First Major Actions in March 2026

The FDA issued 14 warning letters to wholesale drug distributors and third-party logistics providers on March 12, 2026, marking the first major enforcement wave under the Drug Supply Chain Security Act (DSCSA) following the November 27, 2024 deadline for full electronic interoperable compliance. The actions target entities that failed to implement required serialization and verification systems, signaling the end of the informal grace period many distributors relied on.

Regulatory Background

The DSCSA, enacted under Title II of the Drug Quality and Security Act (Public Law 113-54), established requirements for pharmaceutical supply chain partners to create an electronic, interoperable system for identifying and tracing prescription drugs distributed in the United States. The final compliance deadline—November 27, 2024—required wholesale distributors to:

• Capture and maintain transaction information, transaction history, and transaction statements (TI/TH/TS) in electronic format
• Verify product identifier authenticity at the package level upon receipt
• Implement systems capable of responding to verification requests within 24 hours
• Maintain six-year electronic records in EPCIS-compatible format

FDA issued guidance documents in 2023 outlining expectations for systems validation and data integrity but did not publicly commit to a specific enforcement timeline. The March 2026 actions represent the first formal enforcement under 21 U.S.C. § 360eee-1.

Enforcement Actions Detail

The 14 warning letters cite three primary violations:

1. Failure to implement verification systems (9 entities) — Distributors unable to demonstrate functional product identifier verification at the package level. FDA inspections found manual processes or paper-based verification systems still in use 16 months after the deadline.

1. Inadequate transaction data capture (11 entities) — Systems lacking standardized EPCIS format or inability to provide complete TI/TH/TS data upon request. In two cases, distributors were using spreadsheet-based tracking systems that did not meet interoperability requirements under 21 CFR § 582.

1. Non-compliance with verification request timelines (7 entities) — Failure to respond to trading partner verification requests within the mandated 24-48 hour windows. FDA testing involved submitting verification requests to entities suspected of non-compliance; response times ranged from 5-14 days or no response.

Six entities received citations for multiple violations. The warning letters require corrective action plans within 15 business days and follow-up documentation of remediation within 90 days. FDA has not yet issued monetary penalties but stated that "continued non-compliance may result in enforcement actions including suspension of registration under 21 U.S.C. § 360."

Impact on Wholesale Distributors and 3PLs

Entities still operating pre-DSCSA systems face immediate operational risk. The warning letters establish that FDA is actively testing distributor systems through inspection and verification requests—distributors cannot assume non-compliance will remain undetected.

For 3PLs handling DSCSA compliance on behalf of clients, the actions clarify that contractual delegation does not eliminate distributor responsibility. Three of the 14 cited entities had engaged third-party DSCSA service providers but remained liable for system failures. FDA's position: the distributor holding the wholesale drug distributor license under state law bears ultimate compliance responsibility, regardless of outsourcing arrangements.

Distributors currently in the midst of system implementation should note FDA's enforcement focus on verification capability and response times. Paper-based processes, even if partially compliant, do not satisfy the electronic interoperability requirement. Systems must demonstrate real-time serialization verification and automated response to verification requests.

The 90-day remediation window in the warning letters suggests FDA expects rapid deployment of compliant systems. Entities that received warning letters must not only implement technology but also validate system performance and provide documentation to FDA—a process that typically requires 60-90 days even with vendor support.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA establishment registration—a baseline compliance signal but not proof of DSCSA system implementation. The March 2026 enforcement actions highlight a gap ColdChainCheck has observed in directory data: FDA registration does not verify serialization capability or verification system functionality.

The average compliance score across all tracked entities is 51/100. This places the majority of distributors in the "Fair" tier—indicating verified licensure and registration but limited verification of advanced compliance signals like NABP accreditation or clean enforcement records. Only 63 entities in the directory hold NABP Verified-Accredited Wholesale Distributor (VAWD) accreditation, which includes verification of electronic pedigree systems but does not explicitly audit full DSCSA compliance. The score distribution breaks down as follows:

• Excellent (80-100 pts): 28 entities (2.2%)
• Good (60-79 pts): 281 entities (22.0%)
• Fair (40-59 pts): 919 entities (72.1%)
• Poor (20-39 pts): 38 entities (3.0%)
• Minimal (<20 pts): 9 entities (0.7%)

The concentration of entities in the Fair tier suggests widespread baseline compliance (state licenses, FDA registration) but limited verification of operational readiness for DSCSA serialization requirements. The 14 warning letters represent 1.1% of tracked entities—a small enforcement sample, but FDA's historical pattern is to escalate after initial warning letter rounds.

Compliance Officer Action Items

QA managers and procurement teams should take the following steps in response to the March 2026 enforcement wave:

• Audit current trading partners — Use the ColdChainCheck directory to verify that wholesale distributors and 3PLs in your supply chain hold active FDA registration and current state licenses. Entities with expired licenses or suspended registrations carry elevated enforcement risk.

• Request DSCSA system documentation — Ask trading partners for written confirmation of serialization verification capability and EPCIS data format compliance. The warning letters demonstrate FDA expects functional systems, not implementation roadmaps.

• Test verification response times — Submit test verification requests to key distributors and document response times. The 24-hour requirement is now an enforced standard, not a guideline. Partners unable to respond within this window may be operating non-compliant systems.

• Monitor for additional enforcement — FDA typically issues warning letters in waves. ColdChainCheck tracks enforcement actions and updates entity records when warning letters or consent decrees are published. Check the compliance guides section for ongoing DSCSA enforcement coverage.

Entities with compliance scores below 40 warrant additional due diligence. Low scores indicate missing or expired licenses, which may correlate with DSCSA system gaps.

This article is provided for informational purposes only and does not constitute legal or regulatory advice. Verify all compliance requirements with the FDA, relevant state boards of pharmacy, and qualified legal counsel.

Update: DSCSA Full Enforcement 2026: Distributor Requirements

March 19, 2026

DSCSA Full Enforcement Now Active: What Wholesale Drug Distributors Must Know in 2026

As of November 27, 2025, the Drug Supply Chain Security Act (DSCSA) is under full enforcement, completing a phased implementation that began in 2013. The FDA now requires all trading partners—manufacturers, wholesale distributors, repackagers, and dispensers—to operate within an interoperable, electronic system for tracing prescription drugs at the package level. Wholesale drug distributors that fail to maintain DSCSA compliance face regulatory enforcement including warning letters, import alerts, and potential debarment from the pharmaceutical supply chain.

Regulatory Background

The DSCSA (Title II of the Drug Quality and Security Act, Public Law 113-54) established a phased 10-year timeline to build an electronic, interoperable system for identifying and tracing prescription drugs distributed in the United States. The statute directed the FDA to implement unit-level traceability requirements under 21 USC 360eee et seq., replacing the legacy pedigree systems that varied by state.

The November 27, 2025 deadline marked the final implementation milestone: the Enhanced Drug Distribution Security (EDDS) requirements. Under EDDS, wholesale distributors must verify product identifiers at the package level, maintain transaction history electronically, and participate in suspect product investigations using serialized data.

What Changed on November 27, 2025

Prior to November 2025, wholesale distributors operated under lot-level traceability requirements. Transaction documentation included the proprietary or established name of the product, strength and dosage form, container size, number of containers, lot number, transaction date, and shipment date—but not unique serialized package identifiers.

Under full DSCSA enforcement, wholesale distributors must now:

1. Verify product identifiers — Before a wholesale distributor accepts ownership of a product, the distributor must verify that the product identifier (including the standardized numerical identifier, or SNI) corresponds to the product identifier affixed or imprinted by the manufacturer or repackager (21 USC 360eee-1(d)(1)(A)).

1. Maintain serialized transaction data — Transaction information (TI), transaction history (TH), and transaction statements (TS) must be captured and stored in electronic, interoperable formats. Paper-based systems are no longer compliant for products entering the supply chain after November 2025.

1. Respond to verification requests — Wholesale distributors must respond to verification requests from the FDA or other trading partners within 24 hours for suspect products and 48 hours for illegitimate products, providing transaction data at the serialized package level.

1. Quarantine and investigate — Upon discovering a product that does not bear a valid product identifier, distributors must quarantine the product, investigate, and notify the FDA and immediate trading partners within 24 hours (21 USC 360eee-1(d)(3)).

1. Participate in interoperable systems — Trading partners must exchange EPCIS (Electronic Product Code Information Services) data in a format that allows verification through third-party verification router services (VRS) or direct trading partner connections.

Operational Impact on Wholesale Drug Distributors

The shift to serialized verification requires infrastructure investment in barcode scanners, data aggregation systems, and VRS connections. Distributors handling high-volume prescription drug transactions must validate serialized data at receiving, storage, and shipping stages. For distributors operating legacy warehouse management systems (WMS), integration with EPCIS-compliant platforms is now mandatory.

Distributors that have not implemented DSCSA-compliant systems face three immediate risks:

• Trading partner exclusion — Manufacturers and dispensers can refuse to transact with non-compliant distributors to avoid their own compliance violations.
• FDA enforcement — The FDA has signaled that post-deadline enforcement will focus on entities with prior warning letters or a history of non-compliance with cGMP or state licensure requirements.
• Data liability — Distributors that provide inaccurate or incomplete serialized transaction data to downstream partners may be liable under state and federal drug tracing laws, particularly in suspect product investigations.

Distributors must also maintain DSCSA compliance alongside existing obligations: state wholesale drug distributor licensure, FDA registration and listing under 21 CFR Part 207, and NABP accreditation (for entities pursuing Verified-Accredited Wholesale Distributors status). DSCSA enforcement does not replace these requirements—it layers on top of them.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration—a baseline DSCSA requirement under 21 USC 360(b)–(d). However, FDA registration alone does not confirm DSCSA serialization capability. The compliance signals tracked in ColdChainCheck scores (state licensure, NABP accreditation, recall history, enforcement actions) indicate regulatory posture but do not directly measure EPCIS infrastructure or VRS participation.

The average compliance score across all entities in the directory is 51/100, placing the majority of tracked distributors in the "Fair" tier. Score distribution shows:

• 28 entities (2.2%) in the Excellent tier (80-100 pts)
• 281 entities (22.0%) in the Good tier (60-79 pts)
• 919 entities (72.1%) in the Fair tier (40-59 pts)
• 38 entities (3.0%) in the Poor tier (20-39 pts)
• 9 entities (0.7%) in the Minimal tier (0-19 pts)

This concentration in the Fair tier reflects a common pattern: most distributors hold active state licenses and FDA registration but lack NABP accreditation (only 63 entities hold current NABP Accreditation of Wholesale Distributors status). NABP accreditation is not a DSCSA requirement, but entities with accreditation demonstrate higher compliance posture across multiple dimensions, including facility audits and quality system documentation.

Of the 1,275 entities tracked, 73 have at least one FDA recall on record. Post-DSCSA enforcement, entities with recall history face heightened scrutiny during suspect product investigations, as the FDA can now trace serialized packages through the supply chain to identify where verification or quarantine processes failed.

Practical Guidance for QA and Compliance Teams

• Verify DSCSA-specific capabilities during vendor qualification — FDA registration confirms the entity is registered to handle drugs, but does not confirm EPCIS implementation. Ask prospective distributors for documentation of their VRS participation, barcode scanning infrastructure, and EPCIS data exchange workflows. Cross-reference entity compliance scores in the ColdChainCheck directory as a starting point, but follow up with serialization-specific questions.

• Review transaction data handling for existing trading partners — If your organization currently works with distributors in the Fair or Poor compliance tiers, audit whether they are providing serialized TI/TH/TS in EPCIS format. Non-compliant trading partners expose your organization to regulatory risk if the FDA requests transaction data during a suspect product investigation.

• Monitor enforcement actions — ColdChainCheck tracks FDA warning letters and state enforcement actions. Entities with recent enforcement history may be prioritized for DSCSA compliance inspections. Use the directory's enforcement signal filters to identify high-risk trading partners before entering new contracts.

• Document your own due diligence — When state boards of pharmacy or FDA inspectors audit your vendor qualification process, they expect documented evidence that you verified trading partner compliance. A ColdChainCheck compliance score is not sufficient on its own, but it provides a reproducible, timestamped data point showing you checked publicly available compliance signals. Export entity profiles for your QMS documentation trail.

ColdChainCheck does not currently track EPCIS participation or VRS connections—these data sources are not publicly available. The compliance score reflects state licensure, NABP accreditation, FDA registration, recall history, and enforcement actions. For DSCSA-specific verification, consult the entity's DSCSA compliance statement directly and request third-party audit documentation. Additional DSCSA implementation guidance is available in the ColdChainCheck compliance guides.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Verify all compliance requirements with the FDA, relevant state boards of pharmacy, and qualified legal counsel before making operational decisions.

Update: DSCSA Compliance Inspections 2025 | FDA Targets — ColdChainCheck

April 4, 2026

DSCSA Enforcement Shifts to Operational Compliance: What FDA Inspections Are Targeting in 2025

FDA's Drug Supply Chain Security Act inspections in 2025 have shifted from verifying policy documentation to auditing real-time operational performance and data quality. Distributors that built DSCSA compliance programs around Standard Operating Procedures and annual training are now facing citations for failure to demonstrate functional interoperability, accurate transaction history transmission, and timely verification system responses.

Regulatory Context: From Enhanced Drug Distribution Security to Enhanced Drug Distribution Security in Action

The DSCSA (Public Law 113-54, codified at 21 U.S.C. § 360eee et seq.) established November 27, 2023, as the compliance date for enhanced drug distribution security requirements under Section 582(g). These requirements mandate that wholesale distributors verify product identifiers at the package level, maintain electronic transaction information, and participate in product tracing investigations within regulatory timeframes.

The first full calendar year of enforcement — 2024 — focused primarily on whether entities had established written procedures and training programs addressing DSCSA requirements. FDA's limited inspection resources targeted high-risk facilities, and citations clustered around documentation gaps: missing SOPs, inadequate training records, and failure to conduct supplier qualification.

In 2025, FDA has reallocated inspection priorities. Current inspections emphasize operational execution: can the distributor actually verify serialized products in real time? Do their systems generate accurate ATP (authorized trading partner) verification reports? Can they respond to a verification request within 24 hours as required under 21 U.S.C. § 360eee-1(d)(4)(C)?

What Changed in FDA DSCSA Inspections

Three enforcement patterns have emerged in FDA's 2025 inspection cycle:

1. Data Quality Over Data Existence

Inspections now include unannounced verification system tests. FDA investigators arrive with sample product serial numbers and request real-time verification through the distributor's VRS (verification router service) or direct manufacturer connection. Distributors that maintain verification systems for compliance theater — systems that exist but produce error rates above 15% or timeout failures — are receiving Form 483 observations.

Citations reference 21 CFR 1271.155(a), which requires records to be accurate, and apply that standard to EPCIS (Electronic Product Code Information Services) data quality. A distributor cannot claim DSCSA operational readiness if their transaction data contains mismatches between GTINs (Global Trade Item Numbers), serial numbers, and lot numbers at a rate that prevents downstream verification.

2. Interoperability Testing Under Inspection Conditions

FDA is testing whether distributors can exchange transaction information (TI), transaction history (TH), and transaction statements (TS) with trading partners they do not regularly transact with. Inspectors request proof of successful data exchange with at least three distinct manufacturers or repackagers, including validation that the distributor's system can parse and store incoming serialized data from different EPCIS format variations.

Distributors relying on a single solution provider's closed ecosystem — where they only exchange data with entities on the same platform — are being cited for insufficient interoperability infrastructure.

3. Investigation Response Timelines

Under 21 U.S.C. § 360eee-1(c)(4), wholesale distributors must provide transaction information and transaction statements "not later than 1 business day" after receiving a request during a suspect or illegitimate product investigation. FDA inspections now include simulated investigation requests.

Distributors that meet the 24-hour deadline with incomplete data — missing lot numbers, incorrect trading partner identifiers, or TI/TH/TS packages that do not match the requested product — are being cited for non-compliance. The statute requires provision of the requested documentation, not provision of whatever incomplete records are easiest to retrieve.

Operational Implications for Wholesale Distributors

Wholesale drug distributors must shift compliance strategy from policy adherence to operational proof. The following operational readiness gaps are generating the majority of 2025 FDA citations:

Verification System Performance: Distributors must monitor VRS query success rates, timeout frequencies, and data mismatch errors. A verification system with a 70% success rate meets the technical definition of "implemented" but fails the operational standard of "functional."

Cross-Platform Data Exchange: Distributors transacting with manufacturers or repackagers on different DSCSA solution platforms must validate that their system can ingest EPCIS 1.2 and EPCIS 2.0 formats, handle both REST API and AS2 transmission protocols, and reconcile data from partners using different master data sources.

Investigation-Ready Data Retrieval: Distributors must be able to locate and export complete TI/TH/TS packages for any product in inventory within 24 hours. This requires indexed storage by product identifier (GTIN + serial + lot) and trading partner DUNS or GLN, not chronological filing by invoice date.

What ColdChainCheck Data Shows About DSCSA Operational Readiness

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 U.S. jurisdictions. Of these entities, 1,234 hold active FDA registration — a baseline requirement under 21 U.S.C. § 360(9) but not a direct indicator of DSCSA operational compliance.

The average compliance score across all tracked entities is 51/100, placing the majority of the industry in the "Fair" tier. This score reflects verified licensure, accreditation, and registration data — not DSCSA interoperability or verification system performance, which are not publicly disclosed metrics. Only 63 entities hold NABP accreditation (formerly VAWD), which includes a voluntary DSCSA readiness assessment component. This represents 4.9% of the tracked population.

The score distribution reveals concentration in the "Good" (281 entities, 22%) and "Fair" (919 entities, 72%) tiers. Entities in the "Fair" tier typically hold active state licenses and FDA registration but lack NABP accreditation or have limited publicly available compliance signals. This suggests a large segment of the industry may be meeting baseline regulatory requirements without independent third-party validation of operational systems.

73 entities in the directory have at least one FDA recall, warning letter, or enforcement action on record. While not all recalls indicate DSCSA non-compliance, entities with enforcement history may face heightened scrutiny in FDA's 2025 inspection cycle.

Practical Steps for Compliance Officers

• Audit trading partner DSCSA readiness: Use the ColdChainCheck directory to check whether current and prospective distributors hold NABP accreditation. While accreditation does not guarantee operational compliance, it signals investment in third-party verification of DSCSA systems.

• Document verification system performance internally: If your organization sources from distributors scored below 50, request proof of VRS query success rates and EPCIS data exchange testing results. The compliance score reflects static licensing data; operational readiness requires direct validation.

• Cross-reference enforcement history: Entities with FDA warning letters or recalls on record may be under closer inspection scrutiny. Filter the directory by enforcement actions to identify potential risk flags in your supply chain.

• Monitor state board disciplinary actions: ColdChainCheck tracks state pharmacy board enforcement actions, which may include DSCSA-related citations before they appear in FDA records. States with active enforcement programs (Ohio, California, Texas) publish disciplinary orders that can serve as early warning indicators.

ColdChainCheck updates enforcement action data monthly. For comprehensive DSCSA operational requirements, see the DSCSA compliance checklist for wholesale distributors and individual entity profiles in the directory.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Entities should consult qualified legal counsel and verify all compliance requirements with the relevant regulatory authorities.

Update: FDA DSCSA Enforcement Discretion 2026 | Impact — ColdChainCheck

April 6, 2026

FDA Grants DSCSA Enforcement Discretion: What Wholesale Drug Distributors Need to Know

On November 27, 2024, FDA announced it would exercise enforcement discretion for certain Drug Supply Chain Security Act (DSCSA) requirements that took effect November 27, 2023. This discretion applies to product tracing requirements, verification obligations, and product identifier systems—three core compliance areas wholesale drug distributors were required to implement over a year ago.

Regulatory Background

The Drug Supply Chain Security Act (Title II of the Drug Quality and Security Act, Public Law 113-54) established a phased implementation of an electronic, interoperable system for tracing prescription drugs distributed in the United States. Section 582 of the Federal Food, Drug, and Cosmetic Act outlines requirements for wholesale distributors, including:

• Transaction information, transaction history, and transaction statement (TI/TH/TS) obligations under 21 U.S.C. § 360eee-1(c)
• Product identifier requirements (standardized numerical identifier, lot number, expiration date) under 21 U.S.C. § 360eee-1(a)(8)
• Product verification requirements under 21 U.S.C. § 360eee-1(d)
• Systems and processes for serialized tracing under 21 U.S.C. § 360eee-1(c)(4)

The final implementation deadline for enhanced drug distribution security requirements was November 27, 2023. This deadline mandated unit-level product tracing using serialized data in an interoperable electronic format.

Key Details of the Enforcement Discretion

FDA's enforcement discretion applies to three specific areas:

Product Tracing Requirements (Enhanced TI/TH/TS): FDA will not enforce unit-level serialized tracing requirements under 21 U.S.C. § 360eee-1(c)(4)(A) against wholesale distributors who continue to use lot-level aggregated data instead of serialized product identifiers. This effectively allows continued use of the pre-November 2023 transaction data format.

Product Verification: FDA will not enforce requirements to verify product identifiers at the package level under 21 U.S.C. § 360eee-1(d)(1)(B)(iii) for routine transactions. Verification obligations remain in effect for suspect or illegitimate product investigations.

Product Identifier Systems: FDA will not enforce requirements for wholesale distributors to have systems capable of accepting, storing, and transmitting DSCSA-compliant product identifiers in the standardized format.

The enforcement discretion does not include a specified end date. FDA stated it will provide notice before resuming enforcement, but did not commit to a timeline.

Impact on Wholesale Drug Distributors

This announcement creates immediate operational and compliance questions for wholesale distributors:

System Investment Decisions: Distributors who delayed investment in serialized tracing systems pending the November 2023 deadline now face uncertainty about when to deploy these systems. Capital expenditures planned for DSCSA compliance may require re-evaluation.

Trading Partner Agreements: Distributors who negotiated data exchange formats based on the November 2023 requirements may need to revisit agreements. Some trading partners may have already implemented serialized systems; others may not have. This creates potential interoperability mismatches across the supply chain.

Verification Workflows: Distributors who implemented verification processes for serialized product identifiers must now determine whether to maintain these processes or revert to lot-level verification. Dual systems may be necessary if some trading partners provide serialized data while others do not.

Regulatory Compliance Posture: Enforcement discretion is not a regulatory exemption. Distributors must assess whether to comply with the statutory requirements despite FDA's discretion policy, or whether to operate under the discretion parameters. This decision has implications for audits, state board requirements, and accreditation standards.

State Board Alignment: State boards of pharmacy may enforce DSCSA requirements independently of FDA's enforcement discretion. Distributors licensed in multiple states must verify whether state-level requirements remain in effect.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in ColdChainCheck's directory, 1,234 hold active FDA establishment registration—a baseline requirement for DSCSA participation. However, the average compliance score of 51/100 indicates that many entities show gaps in other verifiable compliance signals beyond basic registration.

The score distribution reveals compliance readiness concentration: 28 entities (2.2%) score in the Excellent tier (76-100 points), while 919 entities (72.1%) fall in the Fair tier (26-75 points). This suggests that most wholesale distributors in the directory maintain basic licensure and registration but lack additional compliance signals such as NABP accreditation or clean enforcement records. The enforcement discretion announcement may disproportionately affect entities in the Fair tier, which may have delayed serialization system investments while maintaining baseline compliance.

Only 63 entities (4.9%) hold NABP accreditation—a voluntary standard that includes DSCSA readiness criteria. This small accreditation subset suggests that industry-wide serialization system implementation may be lower than the November 2023 statutory deadline implied. FDA's decision to exercise enforcement discretion aligns with this data: if only 4.9% of tracked entities have undergone accreditation that verifies DSCSA systems, broader industry implementation rates are likely insufficient for enforcement.

Immediate Action Items for Compliance Officers

• Verify trading partner DSCSA posture: Use the ColdChainCheck directory to confirm whether your upstream and downstream partners have FDA registration and NABP accreditation. Partners with accreditation are more likely to have implemented serialized systems; those without may still be operating on lot-level data.

• Document your compliance approach: Determine whether your organization will maintain serialized tracing systems despite enforcement discretion or revert to lot-level processes. Document this decision with reference to FDA's enforcement discretion announcement and your trading partner requirements.

• Monitor state board requirements: Check licensing requirements in each state where you hold a wholesale drug distributor license. State boards may not align with FDA's enforcement discretion. ColdChainCheck tracks state-level license status for all entities in the directory.

• Review vendor qualification SOPs: If your vendor qualification process requires DSCSA-compliant systems, update qualification criteria to reflect enforcement discretion parameters. Cross-reference vendor claims against ColdChainCheck's compliance score breakdown (FDA registration, NABP accreditation, enforcement history).

ColdChainCheck continues to track FDA enforcement actions, NABP accreditation updates, and state licensure changes. For related DSCSA compliance guidance, see the DSCSA compliance checklist for wholesale distributors.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult qualified legal counsel and verify all compliance requirements with the relevant federal and state authorities.

Update: DSCSA Implementation Timeline 2025 | Full Guide — ColdChainCheck

April 6, 2026

DSCSA Implementation Timeline 2025: What Wholesale Distributors Must Do Now

The Drug Supply Chain Security Act reaches full implementation on November 27, 2024, requiring wholesale drug distributors to complete unit-level serialization and transaction data exchange across all trading partners. Distributors operating without full EPCIS-compliant systems after this date face enforcement action from state boards of pharmacy and potential FDA warning letters.

Regulatory Background

The DSCSA was enacted on November 27, 2013 under Title II of the Drug Quality and Security Act (Public Law 113-54). The law established a phased 10-year implementation timeline to create an electronic, interoperable system for identifying and tracing prescription drugs distributed in the United States.

Enforcement authority is split between FDA and state boards of pharmacy. FDA regulates manufacturers and repackagers under 21 U.S.C. § 360eee-1. State boards regulate wholesale distributors under 21 U.S.C. § 360eee-2, though FDA retains concurrent authority. States must adopt substantially similar DSCSA requirements or submit variance requests to FDA within one year of enactment.

The DSCSA replaced the older Drug Pedigree requirements established under the Prescription Drug Marketing Act of 1987. Unlike pedigrees—which tracked ownership changes via paper documentation—DSCSA mandates serialized product identifiers and electronic transaction history.

November 2024: Full Implementation Requirements

As of November 27, 2024, wholesale drug distributors must:

Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) Exchange

Distributors must provide TI, TH, and TS to the subsequent purchaser for each transaction. This applies to all prescription drugs except specific exemptions under 21 U.S.C. § 360eee(9).

Unit-Level Serialization Verification

Distributors must verify the product identifier on each package or homogeneous case before distributing. Verification requires EPCIS 1.2 or 2.0 compliant systems capable of reading GS1 DataMatrix barcodes containing GTIN, serial number, lot number, and expiration date.

Enhanced Suspect Product Procedures

When a distributor receives suspect product, they must quarantine and investigate within 24 hours. If illegitimate, the distributor must notify FDA and immediate trading partners within 24 hours and terminate distribution.

Saleable Returns Processing

Returns accepted by a distributor must be verified against the Verification Router Service (VRS) before redistribution. This requirement applies to all returns, including those from dispensers and healthcare entities.

Authorized Trading Partner (ATP) Documentation

Distributors must verify all trading partners are authorized under 21 U.S.C. § 360eee-1(8) before conducting transactions. Verification includes confirming active state wholesale distributor licenses.

Enforcement Timeline

FDA issued draft guidance "Product Identifiers under the Drug Supply Chain Security Act" in March 2018, finalized in November 2018. The guidance clarifies that distributors must verify product identifiers at the package level, not just accept manufacturer-provided aggregated data.

State boards of pharmacy began enforcement on November 27, 2024. As of January 2025, 47 states have adopted DSCSA-compliant wholesale distributor licensing regulations. Ohio, Texas, California, Florida, and Illinois have issued the highest volume of guidance documents to licensed distributors.

FDA announced in December 2024 that it would prioritize enforcement actions against distributors with pattern violations: entities with multiple suspect product reports, entities operating without state licenses, and entities that fail to maintain TI/TH for six years as required under 21 CFR 205.50(g).

Operational Impact on Wholesale Distributors

Distributors without serialization-capable warehouse management systems cannot legally distribute product after November 27, 2024. This affects:

Inventory Systems

Legacy WMS platforms built before 2018 typically lack EPCIS integration. Upgrading requires capital investment in barcode scanners, server infrastructure, and software licensing.

Returns Processing

Saleable returns that previously moved through standard reverse logistics now require VRS verification before re-entering inventory. This adds processing time and requires VRS membership.

Trading Partner Onboarding

Distributors must document ATP verification for every entity in their trading network. This includes maintaining current copies of state licenses and FDA establishment registrations for all suppliers and customers.

Data Storage Requirements

Six-year retention of TI/TH data under 21 CFR 205.50(g) requires distributors to architect scalable database infrastructure. Transaction volumes for mid-size distributors can exceed 10 million serialized units annually.

What ColdChainCheck Data Shows About DSCSA Readiness

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain providers across 51 jurisdictions. As of January 2025, the average compliance score is 51/100, placing most entities in the "Fair" tier—meaning basic licensure is verified but fewer secondary compliance signals are documented.

Of the 1,275 tracked entities, 1,234 hold active FDA establishment registrations. This represents 97% registration coverage, suggesting broad awareness of federal requirements. However, FDA registration alone does not confirm DSCSA serialization capability or EPCIS implementation.

Only 63 entities (5%) hold NABP accreditation. While NABP accreditation is not legally required for DSCSA compliance, accredited distributors undergo third-party audits covering serialization systems, returns processing, and ATP verification—the same operational areas now under DSCSA enforcement. The low accreditation rate suggests most distributors are managing DSCSA implementation without third-party validation.

73 entities (6%) have FDA recalls, warning letters, or enforcement actions on record. This does not indicate DSCSA-specific violations—most recorded actions predate November 2024 enforcement—but it does flag entities with prior regulatory exposure.

The compliance score distribution shows:

• 28 entities (2%) scored Excellent (76-100 pts)
• 281 entities (22%) scored Good (61-75 pts)
• 919 entities (72%) scored Fair (41-60 pts)
• 38 entities (3%) scored Poor (21-40 pts)
• 9 entities (1%) scored Minimal (0-20 pts)

This distribution reflects data availability, not DSCSA readiness. A "Fair" score means ColdChainCheck has verified state licenses and FDA registration but lacks visibility into NABP accreditation, serialization infrastructure, or EPCIS certification. These are critical DSCSA implementation factors that public databases do not capture.

Practical Guidance for Compliance Officers

Verify ATP Status Before Conducting Transactions

Use the ColdChainCheck directory to confirm trading partners hold active state wholesale distributor licenses. Filter by state and license status. Cross-reference license numbers against state board databases to confirm issue and expiration dates.

Document License Verification in ATP Files

DSCSA requires written verification that trading partners are authorized under 21 U.S.C. § 360eee-1(8). ColdChainCheck data provides a starting point but does not replace direct confirmation. Print or export entity profiles to include in ATP qualification packages.

Monitor for Enforcement Actions

Entities with FDA warning letters or state board actions may indicate compliance risk. ColdChainCheck flags 73 entities with enforcement history. Review the "Recalls & Enforcement" section of each entity profile before onboarding new trading partners.

Track License Renewals

State wholesale distributor licenses expire annually or biennially depending on jurisdiction. ColdChainCheck displays expiration dates where available. Set calendar reminders to re-verify ATP licenses 30 days before expiration to avoid transacting with lapsed entities.

For a complete breakdown of DSCSA serialization, ATP verification, and returns processing requirements, see the DSCSA Compliance Checklist for Wholesale Distributors.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult legal counsel and verify all compliance requirements with the relevant federal and state regulatory authorities.

Update: DSCSA Enforcement Timeline 2026 | FDA Stabilization — ColdChainCheck

April 19, 2026

FDA DSCSA Enforcement Timeline 2026: What Wholesale Distributors Need to Know

FDA announced a phased enforcement approach for DSCSA verification requirements during calendar year 2026, formally designated as a "stabilization period" following the November 27, 2024 implementation deadline. Wholesale drug distributors must understand which requirements remain fully enforceable and which receive temporary enforcement discretion as the agency addresses industry-wide systems interoperability challenges.

Regulatory Background

The Drug Supply Chain Security Act (DSCSA), enacted as Title II of the Drug Quality and Security Act of 2013, established an electronic, interoperable system for identifying and tracing prescription drugs as they move through the U.S. supply chain. Under 21 U.S.C. § 360eee-1, wholesale distributors must verify product at the package level before distribution, conduct investigations of suspect and illegitimate products, and maintain transaction information, transaction history, and transaction statements (collectively, "transaction documentation") in electronic, interoperable formats.

The enhanced drug distribution security (EDDS) requirements—commonly called "DSCSA 2.0"—took effect November 27, 2024. These requirements mandate:

1. Product identifier verification at the package level prior to distribution
2. Verification response system (VRS) participation for ATP verification
3. EPCIS 1.2-compliant transaction data exchange
4. Saleable returns processing with full verification
5. Exception handling for product identifiers that fail verification

FDA initially delayed enforcement of certain EDDS requirements from the statutory November 27, 2023 deadline to November 27, 2024 via guidance documents issued in 2022 and 2023. The 2026 enforcement timeline represents a second phase of enforcement flexibility.

2026 Enforcement Approach

FDA's January 2025 guidance document titled "Compliance Policy for Enhanced Drug Distribution Security Requirements During the Stabilization Period" outlines enforcement discretion across four categories:

Fully Enforceable (No Discretion):

• Transaction documentation requirements under 21 U.S.C. § 360eee-1(c)(1)
• Suspect and illegitimate product investigation requirements under 21 U.S.C. § 360eee-1(b)
• Quarantine and disposition requirements for verified illegitimate products
• Authorized trading partner (ATP) verification before transactions

Enforcement Discretion Through June 30, 2026:

• Package-level verification failures when the distributor documents attempts to verify via VRS and the manufacturer's system is non-responsive
• Product identifier mismatches where the distributor maintains records of verification attempts and alternate verification methods (e.g., 2D barcode scan plus manufacturer confirmation)
• EPCIS message format errors when the distributor can demonstrate the transaction data content is complete and accurate, even if the XML structure is non-compliant

Enforcement Discretion Through December 31, 2026:

• Saleable returns verification when the distributor operates a compliant verification process for new distributions and documents why a returned unit cannot be verified (e.g., damaged barcode, manufacturer system unavailable)
• Interoperability failures between trading partners' systems when both parties document good-faith efforts to establish connectivity

No Enforcement Discretion After December 31, 2026:

All EDDS requirements become fully enforceable beginning January 1, 2027. FDA explicitly states it will not extend the stabilization period beyond 2026.

Operational Implications for Wholesale Distributors

Wholesale drug distributors must implement several compliance steps during 2026 to avoid enforcement action in 2027:

Immediate (Q1 2026):

• Document all verification attempts, including VRS queries, manufacturer system responses, and alternative verification methods used under enforcement discretion
• Establish written procedures defining when enforcement discretion applies and how staff escalate verification failures
• Begin quarterly internal audits measuring verification success rates by product, manufacturer, and verification pathway

By June 30, 2026:

• Achieve >95% package-level verification success rate for new distributions (FDA has indicated this benchmark in informal industry discussions, though not codified in guidance)
• Resolve interoperability issues with top trading partners representing 80% of transaction volume
• Implement automated alerts for products with repeated verification failures to identify manufacturer system issues early

By December 31, 2026:

• Achieve full EPCIS 1.2 compliance for all outbound transaction data
• Establish saleable returns verification workflow with manufacturer coordination for units that cannot be verified via standard VRS processes
• Complete ATP verification for all active trading partners with documented VRS enrollment confirmation

Distributors that fail to meet these milestones risk enforcement action beginning January 1, 2027. FDA has stated that warning letters will cite specific DSCSA violations and that consent decrees may include mandatory compliance monitoring for repeat violators.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain logistics providers across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration—a foundational DSCSA requirement that predates the 2024 EDDS implementation. However, FDA registration alone does not indicate DSCSA verification system readiness.

The average compliance score across tracked entities is 51/100, placing the majority in the "Fair" tier. This score reflects verified licensure, accreditation, and registration data—not DSCSA systems capabilities, which are not publicly disclosed by FDA or state boards. The score distribution shows:

• 28 entities (2.2%) scored Excellent (76-100 points)
• 281 entities (22.0%) scored Good (61-75 points)
• 919 entities (72.1%) scored Fair (41-60 points)
• 38 entities (3.0%) scored Poor (21-40 points)
• 9 entities (0.7%) scored Minimal (0-20 points)

Only 63 entities hold NABP VAWD accreditation (now NABP Accreditation), which requires on-site inspection of wholesale distribution operations. NABP accreditation does not audit DSCSA verification systems specifically, but accredited entities typically maintain more robust quality systems.

73 entities have at least one FDA recall on record. Recalls are not DSCSA violations—they reflect product quality issues—but an entity's recall response procedures overlap with suspect/illegitimate product investigation requirements under 21 U.S.C. § 360eee-1(b), which remain fully enforceable during 2026.

Practical guidance for QA and compliance teams:

• Cross-reference your trading partners against the ColdChainCheck directory to verify active FDA registration and state licensure status. Entities without current registration cannot legally distribute prescription drugs under DSCSA, regardless of enforcement discretion.
• Prioritize NABP-accredited distributors for high-value or high-risk products during the stabilization period. While accreditation does not guarantee DSCSA systems readiness, it signals investment in compliance infrastructure.
• Document verification attempts for all transactions with distributors scored Poor or Minimal. If a trading partner cannot provide transaction data in EPCIS format by Q3 2026, escalate to procurement for alternative sourcing.
• Monitor recall history for trading partners handling temperature-sensitive products. Entities with multiple recalls in ColdChainCheck's database may have quality system gaps that affect their ability to comply with DSCSA exception handling requirements.

ColdChainCheck does not track DSCSA verification system connectivity or VRS participation—this data is not publicly available. Distributors must request DSCSA systems capabilities documentation directly from trading partners. For a complete breakdown of DSCSA compliance requirements and verification workflows, see the DSCSA Compliance Checklist for Wholesale Distributors.

Disclaimer: This article presents regulatory information for educational purposes only. It does not constitute legal or compliance advice. Wholesale drug distributors should consult qualified legal counsel and regulatory affairs professionals regarding DSCSA compliance obligations specific to their operations.